Timed Action of IL-27 Protects from Immunopathology while Preserving Defense in Influenza
Author(s) -
Francesca Diane M. Liu,
Elisabeth E. Kenngott,
Micha F. Schröter,
Anja A. Kühl,
Silke Jennrich,
Ralf Watzlawick,
Ute Hoffmann,
Thorsten Wolff,
Stephen Norley,
Alexander Scheffold,
Jason S. Stumhofer,
Christiaan J. M. Saris,
Jan M. Schwab,
Christopher A. Hunter,
Gudrun F. Debes,
Alf Hamann
Publication year - 2014
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1004110
Subject(s) - immunopathology , immunology , cytokine , viral disease , virus , inflammation , respiratory disease , orthomyxoviridae , medicine , influenza a virus , immune system , biology , lung
Infection with influenza virus can result in massive pulmonary infiltration and potentially fatal immunopathology. Understanding the endogenous mechanisms that control immunopathology could provide a key to novel adjunct therapies for this disease. Here we show that the cytokine IL-27 plays a crucial role in protection from exaggerated inflammation during influenza virus infection. Using Il-27ra −/− mice, IL-27 was found to limit immunopathology, neutrophil accumulation, and dampened T H 1 or T H 17 responses via IL-10–dependent and -independent pathways. Accordingly, the absence of IL-27 signals resulted in a more severe disease course and in diminished survival without impacting viral loads. Consistent with the delayed expression of endogenous Il-27p28 during influenza, systemic treatment with recombinant IL-27 starting at the peak of virus load resulted in a major amelioration of lung pathology, strongly reduced leukocyte infiltration and improved survival without affecting viral clearance. In contrast, early application of IL-27 impaired virus clearance and worsened disease. These findings demonstrate the importance of IL-27 for the physiological control of immunopathology and the potential value of well-timed IL-27 application to treat life-threatening inflammation during lung infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom